Pharmacokinetics of ifosfamide and some metabolites in children

Anticancer Research

Volumn 18, Issue 3 B, 1998, Pages 1941-1949

  Kaijser, G P ^a,b   De Kraker, J ^c   Bult, A ^a,b   Underberg, W J M ^a,b   Beijnen, J H ^d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b CERM Centre Europeen de Recherches Mauvernay   (France)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Children; Ifosfamide; Metabolites; Pharmacokinetics

Indexed keywords

DRUG METABOLITE; IFOSFAMIDE;

ADOLESCENT; ARTICLE; BLOOD BRAIN BARRIER; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG CEREBROSPINAL FLUID LEVEL; DRUG PENETRATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

ADOLESCENT; ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IFOSFAMIDE; MALE; TIME FACTORS;

EID: 0031927278     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Brade WP, Herdrich K, Varini M Ifosfamide-pharmacology, safety and therapeutic potential. Cancer Treat Rev 12: 1-47, 1985.
2. Zalupski M, Baker LH: Ifosfamide. J Nat Cancer Inst 15: 556-566, 1988.
3. Pinkerton CR, Rogers H, James C, Boumann A, Baror PRH, Eden OB, Pritchard J: A phase II study of ifosfamide in children with recurrent solid tumors. Cancer Chemother Pharmacol 15: 258-262, 1985.
4. Allen LM, Creaven PJ, Nelson RL: Studies on the human pharmacokinetics of ifosfamide (NSC-109724). Cancer Treat Rep 60: 451-458, 1976.
5. Nelson RL, Allen LM, Creaven PJ: Pharmacokinetics of divided-dose of ifosfarnide. Clin Pharmacol Ther 19: 365-370, 1975.
6. Varini M. Ifosfamide in tumor therapy-an overview. Contr Oncol 26: 12-21, 1987.
7. Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM: Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res 49: 753-757, 1989.
8. Kurowski V, Cerny T, Kupfer A, Wagner T: Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J Canc Res Clin Onc Supp IV: 1-17, 1991.
9. Lind MJ, Roberts HL, Thatcher N, Idle JR: The effect of route of administration and fractionation of dose on the metabolism of ifosfamide. Cancer Chemother Pharmacol 26: 105-111, 1990.
10. Leblanc GA, Waxman DJ: Mechanisms of cyclophosphamide action on hepatic P450 expression. Cancer Res 50: 5720-5726, 1990.
11. Sladek NE, Doeden D, Powers JF, Krivit W: Plasma concentrations of 4hydroxycyclophosphamide and phosphoramide mustard in patients given repeatedly high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat Rep 68: 1247-1254, 1984.
12. Kaijser GP, Keizer HJ, Beijnen JH, Bult A, Underberg WJM: Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide. Anticancer Res 16: 3247-3258, 1996.
13. Boddy Av, Cole M, Pearson ADJ, Idle JR: The kinetics of the auto-ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacol 36: 53-60, 1995.
14. Kaijser GP, Beijnen JH, Bult A, Wiese G, De Kraker J, Underberg WJM: Gas chromatographic determination of ifosfamide in microvolumes of urine and plasma. J Chromatogr 571: 121-131, 1991.
15. Kaijser GP, Beijnen JH, Bult A, Wiese G, De Kraker J, Keizer HJ, Underberg WJM: Gas chromatographic determination of 2- and 3-dechloroethylifosfamide in plasma and urine. J Chromatogr 583: 175-182, 1992.
16. Kaijser GP, Ter Riet PGJH, de Kraker J, Bult A, Beijnen JH, Underberg WJM: Determination of 4-hydroxyifosfamide in biological matrices by high-performance liquid chromatography. J Pharm Biomed Anal 15: 773-781, 1997.
17. Rowland M, Tozer TN: Metabolite kinetics. In: Clinical pharmacokinetics, concepts and applications". Philadelphia, USA: Lea and Febiger, pp 124-137, 1980.
18. Wagner T, Heydrich D, Jork T, Volcker G, Hohorst HJ: Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test. J Cancer Res Clin Oncol 100: 95-104, 1981.
19. Lewis LD, Fitzgerald DL, Harper PG, Rogers HJ: Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism. Br J Clin Pharmac 30: 725-732, 1990.
20. Boos J, Welslau U, Ritter J, Blaschke G, Schellong G: Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children. Cancer Chemother Pharmacol 28: 455-460, 1991.
21. Norpoth K: Studies on the metabolism of isophosphamide (NSC-109724) in man. Cancer Treat Rep 60: 437-443, 1976.
22. Wagner T, Heydrich D, Volcker G, Hohorst HJ: Uber Blutspiegel und Urinausscheidung von aktiviertem Cyclophosphamide und seinem Deaktivierungs produkten beim Menschen. J Cancer Res Clin Oncol 96: 79-92, 1980.
23. Ninane J, Baurain R, De Kraker J, Ferster A, Trouet A, Cornu G: Alkylating activity in serum, urine and CSF following high-dose ifosfamide in children. Cancer Chemother Pharmacol 24: S2-S6, 1989.
24. Creaven PJ, Allen LM, Alford DA, Cohen MH: Clinical pharmacology of isophosphamide. Clin Pharm Therap 16: 77-86, 1974.